GlobeNewswire by notified

Tilray Medical Relaunches Cannabis Oral Solution Across Ireland

Share

Tilray’s Medical Cannabis Product Now Available and Reimbursed Under Ireland’s Medical Cannabis Access Program

LEAMINGTON, Ontario and CANTANHEDE, Portugal, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced that it has successfully relaunched its EU GMP-produced medical cannabis oral solution in Ireland under the country’s Medical Cannabis Access Program (MCAP). Tilray’s approved product has also recently received reimbursement approval, which gives patients cost reimbursement and ensures more eligible patients can access quality medical cannabis under Ireland’s MCAP.

Denise Faltischek, Tilray Brands’ Chief Strategy Officer and Head of International Business, said, “We are extremely proud to relaunch in Ireland with an expanded footprint. The MCAP reimbursement approval is a tremendous step in providing patients with greater access to Tilray’s high-quality medical cannabis products that address their needs. We remain dedicated to do our part to increase access for patients in need around the world.”

Patients in Ireland may now access Tilray’s full-spectrum medical cannabis oil solution through the MCAP. Tilray intends to supply Irish patients with its full suite of medical cannabis products when local regulations allow.

Tilray Medical is a leading provider of EU-GMP certified medical cannabis products in 22 countries with a comprehensive portfolio of THC and CBD products. Each medical cannabis product that Tilray offers has been selected to ensure patients can receive both the highest product quality as well as consistency when it comes to supply of their medicinal cannabis products.

About Tilray Medical 
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, and Symbios. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first EU-GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 22 countries and across five continents.

For more information on medical cannabis and Tilray Medical, visit www.Tilray.com/tilray-medical and follow @tilraymedical on Instagram.

About Tilray Brands

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time. Tilray Brands delivers on this mission by inspiring and empowering the worldwide community to live their very best life and providing access to products that meet the needs of their mind, body, and soul while invoking wellbeing. Patients and consumers trust Tilray Brands to deliver a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.

For more information on Tilray Brands, visit www.Tilray.com and join the conversation @Tilray.

Forward-Looking Statements

Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things: expectations regarding the performance and scale of the Company, including Tilray Medical; and the Company’s ability to expand its offering to patients worldwide, including via Tilray Medical. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

For further information:

Media
Berrin Noorata
news@tilray.com

Investors
Raphael Gross
203-682-8253
Raphael.Gross@icrinc.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

REPURCHASE OF SHARES7.12.2022 19:30:00 CET | Press release

Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has repurchased53,472 of its own shares in the period from 1December 2022 up to and including7 December 2022 at an average price of €22.33. This is in accordance with the share buyback program originally announced on 22 July 2022 and subsequently increased as per the announcement made on 27 October 2022. The consideration of this purchase was €1.2 million. The total number of shares purchased under this program to date is 757,454 shares at an average price of €20.70 for a total consideration of €15.7 million. 3,543,421 shares were held in treasury as at 7 December 2022. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996149 Email: investor.relations@flowtraders.com About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expanding i

RCI Banque - Press release: THE BOARD OF DIRECTORS OF RCI BANQUE SA APPOINTS PATRICK CLAUDE AS ACTING CHAIRMAN OF THE BOARD OF DIRECTORS OF RCI BANQUE SA7.12.2022 18:39:35 CET | Press release

PRESS RELEASE December 7th 2022 THE BOARD OF DIRECTORS OF RCI BANQUE SA APPOINTS PATRICK CLAUDE AS ACTING CHAIRMAN OF THE BOARD OF DIRECTORS OF RCI BANQUE SA The Nominations Committee of RCI Banque SA acknowledged the resignation of Clotilde Delbos as of December 31, 2022. Patrick Claude, VP Finance of Renault Group and member of the board of RCI Banque SA, has been proposed as acting Chairman of the Board of Directors of RCI Banque SA from January 1, 2023. The Board of Directors of RCI Banque SA, met on December 7 and very warmly thanked Clotilde Delbos her role as Chairman. The Board approved the appointment of Patrick Claude as acting Chairman of the Board of Directors of RCI Banque SA. Patrick Claude was also appointed as acting member of the Nominations Committee and the Remuneration Committee. The appointment of Patrick Claude as acting Chairman of the Board of Directors of RCI Banque SA will be subject to the approval of the European Central Bank. Patrick Claude is a graduate of

Ress Life Investments A/S publishes annual report7.12.2022 18:09:31 CET | Press release

Ress Life Investments A/S Corporate Announcement no. 44/2022 Annual Report 2021/22 http://www.resslifeinvestments.com/ CorporateAnnouncementno.44/2022:AnnualReport1October2021–30 September2022 Copenhagen, 7 December 2022 The Board of Directors and Management have today discussed and approved the Annual Report of Ress Life Investments A/S for the period 1 October 2021 – 30 September 2022. Key results and highlights: Ress Life Investments A/S realised a net profit before and after tax of USD 34,895,871 for the period 1 October 2021 – 30 September 2022. Net profit for the period corresponds to a net return on equity of 10.5% and an increase in net asset value of USD 229 per share. The increase in profit mainly relates to pay-outs of policies offset by administrative expenses and staff costs. The fair value of the Group’s investment assets increased from USD 255,262,257 at 30 September 2021 to USD 303,228,365 at 30 September 2022. The Group’s investments in treasury bills increased from US